ModeX begins dosing within the MDX2003 trial for B-cell lymphoma
OPKO Well being subsidiary ModeX Therapeutics has begun dosing sufferers with its tetraspecific T-cell engager, MDX2003, for relapsed or refractory B-cell lymphoma.
The MDX-2003-101 research will examine the tolerability, pharmacokinetics, security and immune exercise of MDX2003 in grownup sufferers affected by varied types of B-cell lymphoma. It contains each dose escalation and dose growth segments.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
B-cell lymphoma, a type of non-Hodgkin lymphoma that arises from B lymphocytes, accounts for 85% of all circumstances of non-Hodgkin lymphoma.
Roughly 30-40% of those sufferers proceed to expertise relapse, development, or refractory illness after preliminary chemoimmunotherapy.
Giovanni Abbadessa, Chief Medical Officer of ModeX Therapeutics, mentioned: “This scientific trial represents a big milestone for ModeX. MDX2003 is designed to deal with the constraints of present T-cell engagers by combining twin tumor antigen focusing on with optimized T-cell activation. This primary-in-human research will enable us to evaluate security and organic exercise in sufferers with superior B-cell lymphoma.”
The preclinical knowledge supporting MDX2003, together with proof-of-concept findings and the scientific dose choice rationale, had been offered on the American Society of Hematology Annual Assembly 2025 and the ESMO Focused Anticancer Therapies Congress 2026.
MDX2003 is designed to focus on CD19 and CD20 to B cells and CD3 and CD28 to T cells, aiming to beat tumor antigen loss with a twin B cell focusing on technique and promote sturdy T cell activation by way of CD3/CD28 costimulation. Preclinical research have demonstrated sturdy antitumor exercise and balanced T cell activation.
ModeX Therapeutics is growing multi-specific antibody therapies for oncology, immunology and infectious illnesses, focusing on complicated illnesses with first-in-class candidates throughout a spread of indications.
OPKO Well being operates as a world biopharmaceutical and diagnostics firm making use of proprietary applied sciences to giant, fast-growing medical markets.
